(Reuters) – Soligenix Inc said on Tuesday the U.S. Food and Drug Administration (FDA) has declined to review the drug developer’s application for its cancer drug.
The FDA said the company’s application was not sufficiently complete to permit substantive review.
(Reporting by Sriparna Roy in Bengaluru)
